Calculating renal function in patients with atrial fibrillation
This animation has been developed and funded by the Bristol Myers Squibb/Pfizer Alliance and is intended for UK healthcare professionals.
432-GB-2100230 June 2021
COPD: LAMA/LABA therapy—Real life case studies
This promotional resource has been funded and provided by GSK. Information intended for UK healthcare professionals only.
PM-GB-UCV-WCNT-200015 V2.0
Why you might want to review patients with COPD receiving a LAMA
This promotional resource has been funded and provided by GSK. Information intended for UK healthcare professionals only.
PM-GB-UCV-WCNT-200013
COPD: Have you done enough to implement guidelines?
This promotional resource has been funded and provided by GSK. Information intended for UK healthcare professionals only.
PM-GB-UCV-WCNT-200012
Why use LAMA/LABAs as initial maintenance therapy in specific COPD patients?
This promotional resource has been funded and provided by GSK. Information intended for UK healthcare professionals only.
PM-GB-UCV-WCNT-200011
LAMA/LABAs as initial maintenance therapy in COPD
This promotional resource has been funded and provided by GSK. Information intended for UK healthcare professionals only.
PM-GB-UCV-WCNT-200010
The role of peripherally acting µ-opioid receptor antagonists (PAMORAs) in the management of opioid-induced constipation (OIC)
This educational reference document has been initiated, commissioned, and developed by Sandoz Ltd. Information intended for UK healthcare professionals only.
View prescribing information
UK/MKT/RZM/20-0029f October 2020